Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Andrew Murphy

Emergency Medicine Gainesville, FL Medical Doctor

NPI 1568776565 CMS profile 2793533

1600 Sw Archer Rd, Gainesville, FL 32610

Open in the dashboard

General payments

$7,121

8 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Murphy of Gainesville, FL is reported in the CMS Open Payments database as having received $7,121 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $73 3
2024 General $136 1
2023 General $6,667 1
2022 General $245 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Murphy
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Andrew Murphy were reported at $73. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Andrew Murphy Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $0 $29 $16–$99 $114
2021 $0 $40 $18–$124 $132
2022 $245 $49 $20–$134 $149
2023 $6,667 $51 $22–$142 $160
2024 $136 $52 $22–$150 $164
2025 $73 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $6,667 1 payment
  2. Novastep Inc. $223 2 payments
  3. Stryker Corporation $136 1 payment
  4. Boston Scientific Corporation $48 2 payments
  5. HeartFlow, Inc. $25 1 payment
  6. Genentech USA, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Grant $6,667 1 payment
  2. Food and Beverage $454 7 payments
Products named General payments · program years 2022–2025
  1. ENDURANT IIS $6,667 1 payment
  2. PECA Bunion Correction System $223 2 payments
  3. INFINITY ADAPTIS $136 1 payment
  4. LithoVue $26 1 payment
  5. FFRct $25 1 payment
  6. Xofluza $23 1 payment
  7. SpaceOAR VUE System - 10mL $22 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

541

Median for Emergency Medicine: 88

Drug cost

$4,345

Median for Emergency Medicine: $590

Branded share of claims

40.1%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 133 $1,273
Albuterol Sulfate Hfa Albuterol Sulfate Brand 43 $966
Methylprednisolone Generic 90 $539
Cefdinir Generic 26 $472
Azithromycin Generic 80 $298
Cephalexin Generic 33 $289
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 29 $150
Naproxen Generic 48 $121
Doxycycline Hyclate Generic 13 $113
Methocarbamol Generic 22 $83

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$23,642

Of which drugs: $695

Medicare patients

201

Average age 75

Services billed

5,551

116 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Ischemic heart disease 33%
Diabetes 25%
Chronic kidney disease 23%
Depression 23%
Cancer 20%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 41 3,280 $314
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 12 903 $88
Injection, methylprednisolone acetate, 80 mg J1040 Office 12 12 $44
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 56 570 $40
Infusion, normal saline solution , 1000 cc J7030 Office 13 13 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record